CAR T-Cell Immunotherapy and Future Treatment Applications for Brain Tumor Patients

Dr. Charles Cobbs, Neurosurgeon and Director of The Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at Swedish Neuroscience Institute in Seattle discusses CAR T-cell immunotherapy and its application to Brain Tumor treatment. For additional articles on this recent research for brain tumor patients, here are some additional links:

Immunocellular Therapeutics

Immunocellular Therapeutics Phase 3 ICT 107 Vaccine Clinical Trial for Glioblastoma Patients

ICT 107 is a vaccine for glioblastoma cancer stem cells.  This vaccine was developed by a company called ImmunoCellular Therapeutics, ( ) primarily by researchers at Cedars Sinai in Los Angeles.  This protocol has completed phase II testing and now it is open to a phase 3 randomized double blind control study for newly diagnosed glioblastoma.  […]

UCLA researchers develop promising new combo treatment for deadly brain cancer

A recent article,,  by my colleague Dr. Robert Prins at UCLA  in the prestigious journal Neuro Oncology has drawn significant attention.  Dr. Prins works with Dr. Linda Liau at UCLA developing immunotherapy approaches for treating glioblastoma.  Immunotherapy for cancer is a rapidly evolving field.  To the lay person it can be quite confusing.  There […]


Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

Quite a bit of interest has resulted from a recent study performed by investigators at Mayo Clinic and UCSF with respect to various molecular categories of glioblastoma. For the non-aficionado, these studies are very complex and confusing. If you have a PhD in molecular genetics you might understand it. I will attempt to […]

Update on Phase II Trial by Immunocellular Therapeutics ICT 107 for Newly Diagnosed Glioblastoma

Charles S. Cobbs, MD The Gregory Foltz, MD Endowed Director Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment Swedish Neuroscience Specialists   A recent presentation at the American Society for Clinical Oncology  (ASCO) meeting in Chicago this month shows some suggestion of efficacy of the ImmunoCellular Therapeutics immunotherapy vaccine ICT-107.  The vaccine […]